Bridge Biotherapeutics to Present Tuesday at the BIO International Convention
Benzinga Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, will present an overview of its pipeline in multiple disease states on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston June 5-8.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005303/en/
Pavel Printsev, Director of Business Development, will provide a overview of the company's science and an introduction to its clinical-stage assets:
- BBT-176 -- Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations, currently in a Phase I/II dose escalation study
- BBT-877 -- Autotaxin inhibitor for idiopathic pulmonary fibrosis, currently in a Phase IIa trial
- BBT-207 -- Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations, which recently received FDA clearance for a first-in-human Phase I/II
Mr. Printsev will also give an overview of Bridge Biotherapeutics' newly acquired biosensing technology and its plans to commercialize these novel capabilities.
